A novel drug for osteoporosis

Our researchers at NTNU have demonstrated novel CSF1R-inhibitors to efficiently and selectively inhibit CSF1R signaling in a model cell system. We put forward to optimize these novel drug leads into molecules that would be potential osteoporosis drugs for major pharma-companies.

The global osteoporosis drugs market size was accounted for USD 11.5 billion in 2015 and is expected to grow at a CAGR of 3.3%. Future demand for drugs in prophylaxis and treatment is driven by an increasing geriatric population.

• The only osteoporotic drug in the kinase inhibitor class
• Permits alternative to existing drug targets causing unwanted side effects.


  • Patent pending
  • Seeking big pharma companies for clinical testing